Onconetix's Proteomedix Licenses Key Antibody Technology To Immunovia For Pancreatic Cancer Test; In Return, Immunovia Will Make Payments Totaling $700K To Proteomedix In 2025 And 2026, As Well As Pay A 3% Royalty On Net Sales Of PancreaSure And Any Other Products Incorporating The Licensed Intellectual Property From 2026 To 2032

Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG ("Proteomedix") has  signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden.

Under the terms of the agreement, Proteomedix will provide Immunovia with master cells required to produce antibodies related to three of the five biomarkers included in the PancreaSure test and a license for key intellectual property for the manufacturing of reagents used to measure these biomarkers, allowing Immunovia to purchase reagents directly from the supplier of Proteomedix.

In return, Immunovia will make payments totaling $700,000 to Proteomedix in 2025 and 2026, as well as pay a 3% royalty on net sales of PancreaSure and any other products incorporating the licensed intellectual property from 2026 to 2032.